Oral capsule formulation with increased physical stability
View Patent ↗A formulation for a stabilized capsule for oral administration of a hydrophobic pharmaceutically active agent; comprising a non-aqueous solubilizer selected from 2-pyrrolidone, N-alkylpyrrolidones and combinations thereof; and a capsule stabilizing agent selected from mono-, di- and triglycerides, mono- and di-fatty esters of polyethylene glycol, fatty acids and combinations thereof wherein capsule integrity is maintained for at least 24 hours is disclosed.
1. A stabilized capsule for oral administration of a hydrophobic pharmaceutically active agent; wherein said capsule contains a formulation consisting essentially of a hydrophobic pharmaceutically active agent and a solubilizing composition, wherein said solubilizing composition consists essentially of at least one N-alkylpyrrolidone, and a capsule stabilizing agent selected from mono- and diglycerides, mono- and di-fatty esters of polyethylene glycol, fatty esters of propylene glycol, fatty acids and combinations thereof, wherein the stabilizing agent to the N-alkylpyrrolidone weight ratio is from about 1:20 to about 2:1 and wherein said amount of stabilizing agent is sufficient to maintain capsule wall integrity for at least 24 hours.
2. A capsule according to claim 1 wherein said N-alkylpyrrolidone is selected from the group consisting of N-methyl-2-pyrrolidone, N-ethyl-2-pyrrolidone, N-propyl-2-pyrrolidone, N-isopropyl-2-pyrrolidone, N-butyl-2-pyrrolidone, and mixtures thereof.
3. A capsule according to claim 2 wherein said N-alkylpyrrolidone is N-methyl-2-pyrrolidone.
4. A capsule according to claim 1 wherein the capsule stabilizing agent is present in amounts of from about 10% to about 150% by weight with respect to the non-aqueous solubilizer.
5. A capsule according to claim 4 wherein the capsule stabilizing agent is present in amounts of from about 20% to about 100% by weight with respect to the non-aqueous solubilizer.
6. A capsule according to claim 1 wherein the non-aqueous solubilizer is present in sufficient amounts to maintain the hydrophobic pharmaceutically active agent in solution or suspension.
7. A capsule according to claim 1 wherein the non-aqueous solubilizer is a complexing agent, wherein said complexing agent is N-methyl-2-pyrrolidone.
8. A capsule containing a pharmaceutical dosage unit form consisting essentially of a hydrophobic pharmaceutically active agent and a solubilizing composition, wherein said solubilizing composition consists essentially of a non-aqueous solubilizer selected from at least one N-alkylpyrrolidone and a capsule stabilizing agent selected from mono- and diglycerides, fatty esters of polyethylene glycol, fatty esters of propylene glycol, fatty acids or mixtures thereof, wherein the stabilizing agent to the N-alkylpyrrolidone weight ratio is from 1:20 to about 2:1 and wherein said amount of stabilizing agent is sufficient to maintain capsule wall integrity for at least 24 hours.
9. A formulation for a stabilized capsule for oral administration of a hydrophobic pharmaceutically active agent; wherein said capsule contains a formulation consisting essentially of a hydrophobic pharmaceutically active agent, at least one N-C 1-4 alkylpyrrolidone non-aqueous solubilizer, and a capsule stabilizing agent selected from mono- and diglycerides, mono- and di-fatty esters of polyethylene glycol, fatty esters of propylene glycol, fatty acids and combinations thereof, wherein the stabilizing agent to the N-alkylpyrrolidone weight ratio is from about 1:20 to about 2:1 and wherein said amount of stabilizing agent is sufficient to maintain capsule wall integrity for at least 24 hours.